NASDAQ:PRQR
ProQR Therapeutics N.V. Stock News
$1.94
-0.0300 (-1.52%)
At Close: Apr 30, 2024
ProQR Shares Crater After Disappointing Sepofarsen Data In Inherited Vision Loss Disorder
01:44pm, Friday, 11'th Feb 2022 Benzinga
ProQR Therapeutics N.V. (NASDAQ: PRQR ) shares are plunging after disappointing data from its pivotal Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated Leber congenital amaurosis 10 (LCA10). The trial failed to meet its primary endpoint of Best Corrected Visual Acuity (BCVA) at Month 12. Illuminate trial enrolled 36 participants aged eight years or older with … Full story available on Benzinga.com
Affirm Holdings, Cleveland-Cliffs, The Chemours among premarket losers'' pack
01:32pm, Friday, 11'th Feb 2022 Seeking Alpha
ProQR Therapeutics PRQR -69% after the trial for sepofarsen in Leber congenital amaurosis did not meet main goal.Betterware de Mexico BWMX -26% on Q4 earnings release.Hudson…
Why ProQR Therapeutics Is Crashing Today
01:24pm, Friday, 11'th Feb 2022
Sepofarsen's failure to meet efficacy endpoints in the Illuminate trial isn't sitting well with investors.
ProQR says trial for sepofarsen in Leber congenital amaurosis did not meet main goal
12:21pm, Friday, 11'th Feb 2022 Seeking Alpha
ProQR Therapeutics (PRQR) announced on Friday that the company’s pivotal Phase 2/3 Illuminate trial for RNA therapy sepofarsen in EP290-mediated Leber congenital amaurosis 10 (LCA10)…
ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10
12:00pm, Friday, 11'th Feb 2022 GlobeNewswire Inc.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of t
ProQR to Present at Upcoming SVB Leerink Conference
09:30pm, Monday, 07'th Feb 2022 GlobeNewswire Inc.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of tr
ProQR to Present at Upcoming SVB Leerink Conference
04:30pm, Monday, 07'th Feb 2022
LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of tran
Strength Seen in ProQR (PRQR): Can Its 7% Jump Turn into More Strength?
07:11am, Wednesday, 02'nd Feb 2022 Zacks Investment Research
ProQR (PRQR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Strength Seen in ProQR (PRQR): Can Its 7% Jump Turn into More Strength?
03:53am, Wednesday, 02'nd Feb 2022
ProQR (PRQR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen
12:00pm, Tuesday, 04'th Jan 2022 GlobeNewswire Inc.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of tr
ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital
12:00pm, Thursday, 30'th Dec 2021 GlobeNewswire Inc.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) (“ProQR”), a company dedicated to changing lives through the creation of transfor
Is ProQR Therapeutics N.V. (NASDAQ: PRQR) A Stock A New Investor Should Consider Now?
12:30pm, Saturday, 18'th Dec 2021 Stocks Register
ProQR Therapeutics N.V. (NASDAQ:PRQR) shares, rose in value on Friday, 12/17/21, with the stock price up by 6.14% to the previous days close as strong demand from buyers drove the stock to $7.43. Actively observing the price movement in the last trading, the stock closed the session at $7.00, falling within a range of $6.75 Is ProQR Therapeutics N.V. (NASDAQ: PRQR) A Stock A New Investor Should Consider Now? Read More »
ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa
12:00pm, Thursday, 16'th Dec 2021 Intrado Digital Media
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced the first patients dosed in Phase 2/3 Sirius and Celeste clinical trials of investigational RNA therapy QR-421a for people with USH2A mediated retinitis pigmentosa (RP) and Usher syndrome.
ProQR Therapeutics N.V. (PRQR) Probability Sentiment
10:04pm, Saturday, 11'th Dec 2021 GEO Investing
Proqr Therapeutics N.v. (NASDAQ:PRQR) Probability Sentiment SUMMARY In many diseases, discovering the key gene or protein target to treat remains elusive. Not so with the rare eye disease CEP290-mediated Leber congenital amaurosis (LCA10). People with CEP290-mediated LCA10 suffer vision loss because of a specific mutation in the CEP290 gene. The []
Northern Trust Corp Has $91,000 Holdings in ProQR Therapeutics (NASDAQ:PRQR)
09:08am, Tuesday, 07'th Dec 2021 Dakota Financial News
Northern Trust Corp lowered its position in shares of ProQR Therapeutics (NASDAQ:PRQR) by 24.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,481 shares of the biopharmaceutical companys stock after selling 4,432 shares during the quarter. Northern Trust Corps holdings in []